Expert perspectives with Thomas E. Hutson, DO, PharmD, FACP

This independent medical education activity features an expert interview with Thomas E. Hutson, DO, PharmD, FACP, that focuses on a recent publication reviewing the current evidence to support sequential use of targeted agents in patients with advanced renal cell carcinoma. (Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Crit Rev in Oncol Hematol. 2011;77(1):48-62).

Dr Hutson briefly discusses the rationale in choosing the most appropriate sequence of therapies in advanced renal cell carcinoma, how treatment options may be guided by different clinical scenarios following first-line tyrosine kinase inhibitor (TKI) therapy, and how to establish a patient-focused approach to treatment.